非药物和非生物制剂干预的疗效与安全性:为2022年ASAS/EULAR中轴型脊柱关节炎管理推荐更新提供依据的系统文献综述
该系统文献综述(检索2016-2021年)评估了非药物和非生物制剂药物治疗中轴型脊柱关节炎(axSpA)的疗效与安全性,共纳入107篇文献。教育、锻炼和NSAIDs被证实有效,JAK抑制剂(托法替布、乌帕替尼、非戈替尼)在放射学阳性axSpA中有效,而阿普米司特和尼洛替尼无效。
要点
- 教育对疾病活动度、功能和活动度的效应量小到中等(BASDAI ES 0.06-0.59)。
- 锻炼对这些结局的效应量为中到高(BASDAI ES 0.14-1.43)。
- JAK抑制剂在r-axSpA中有效(ASAS20 RR对比安慰剂1.91-3.10)。
核心结论
- 教育和锻炼以及NSAIDs被证实对axSpA有效,JAK抑制剂被证实对r-axSpA有效。
研究设计与样本
- 系统文献综述,检索2016年至2021年(截至2022年1月1日)关于非药物和非生物制剂药物治疗axSpA疗效与安全性的文献。
- 纳入研究类型包括随机对照试验、观察性研究(用于非药物治疗的疗效和安全性)和定性研究。
- 共纳入107篇文献,其中63篇涉及非药物干预(教育n=8,锻炼n=20)。
主要发现
- 教育对疾病活动度、功能和活动度的效应量小到中等(例如BASDAI,ES:0.06-0.59)。
- 锻炼对这些结局的效应量为中到高(例如BASDAI,ES:0.14-1.43)。
- 六项关于靶向合成DMARDs的RCT显示托法替布、乌帕替尼和非戈替尼(仅2期)在r-axSpA中有效(ASAS20的RR对比安慰剂范围:1.91-3.10),而阿普米司特和尼洛替尼无效。
- 关于传统合成DMARDs(n=3)、NSAIDs(n=8)和其他药物(n=12)的研究未提供疗效/安全性的新证据(NSAIDs疗效被确认;一项RCT中短期糖皮质激素疗效有限)。
关键数值与推荐
- 教育对BASDAI的效应量范围为0.06-0.59。
- 锻炼对BASDAI的效应量范围为0.14-1.43。
- 托法替布、乌帕替尼和非戈替尼(仅2期)在r-axSpA中ASAS20的RR对比安慰剂范围为1.91-3.10。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To update the evidence of non-biological treatments for axial spondyloarthritis (axSpA), as a basis for the 2022 Assessment of SpondyloArthritis international Society-European Alliance of Associations for Rheumatology (ASAS-EULAR) recommendations for the management of axSpA. METHODS: A systematic literature review (2016-2021) on efficacy and safety of non-pharmacological and non-biological pharmacological treatments was performed, up to 1 January 2022. The research question was formulated according to the PICO format: Population: adult patients with r-axSpA and nr-axSpA; Intervention: non-pharmacological and non-biological pharmacological treatments; Comparator: active comparator or placebo; Outcomes: all relevant efficacy and safety outcomes. Type of studies included were: randomised controlled trials (RCTs), observational studies (for efficacy of non-pharmacological treatments, and safety), qualitative studies. Cohen's effect size (ES) was calculated for non-pharmacological and risk ratio (RR) for pharmacological treatments. RESULTS: Of 107 publications included, 63 addressed non-pharmacological interventions, including education (n=8) and exercise (n=20). The ES for education on disease activity, function, mobility was small to moderate (eg. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), ES: 0.06-0.59). Exercise had moderate to high ES on these outcomes (eg. BASDAI, ES: 0.14-1.43). Six RCTs on targeted synthetic disease-modifying antirheumatic drugs (DMARDs) showed efficacy of tofacitinib, upadacitinib and filgotinib (phase 2 only) in r-axSpA (range RR vs placebo for ASAS20: 1.91-3.10), while apremilast and nilotinib were not efficacious. Studies on conventional synthetic DMARDs (n=3), non-steroidal anti-inflammatory drugs (NSAIDs, n=8) and other drugs (n=12) did not provide new evidence on efficacy/safety (efficacy of NSAIDs confirmed; limited efficacy of short-term glucocorticoids in one RCT). CONCLUSIONS: Education, exercise and NSAIDs confirmed to be efficacious in axSpA. JAKi were proved efficacious in r-axSpA.
引用
- Ortolan A, Webers C, Sepriano A, et al. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. 2022. PMID: 36261247. doi:10.1136/ard-2022-223297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。